Supernus Pharmaceuticals Inc expected to post earnings of 55 cents a share - Earnings Preview

Supernus Pharmaceuticals

24/02/2024 02:16

* Supernus Pharmaceuticals Inc  SUPN.OQ   SUPN.O  is
expected
to show a fall in quarterly revenue when it reports  results on
February 27 for the period ending December 31 2023
    * The Rockville Maryland-based  company is expected to
report a
7.3% decrease in revenue to $155.031 million from $167.33
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Supernus Pharmaceuticals
Inc
is for earnings of 55 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $41.50​, above​ its last closing price
of $29.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.07        0.08       0.24      Beat    200
 Jun. 30 2023  -0.23       0.07       -0.02     Missed  -130.8
 Mar. 31 2023  0.13        0.17       0.29      Beat    70.6​
 Dec. 31 2022  0.70        0.68       0.43      Missed  -36.8
 ​​Sep.        0.44        0.36       0.03      Missed  -91.6
 30 2022                                                
 Jun. 30 2022  0.33        0.29       0.14      Missed  -51.7​
 Mar. 31 2022  0.25        0.24       0.43      Beat    79.2
 Dec. 31 2021  0.29        0.24       0.04      Missed  -83.1
 This summary was machine generated February 24 at 02:16 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)